ABRAXANE Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation

, today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. The ABRAXANE Marketing Authorisation has been updated across 28 member states in the European Union to include this new indication in non-small cell lung cancer (NSCLC), adding to the existing indications for the treatment of metastatic pancreatic and breast cancers. Lung cancer is the fourth most commonly diagnosed cancer in both men